Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
blog:bpaddock:win_at_the_fda_hearing_on_fluoroquinolone_antibiotics [2015/11/17 01:34] bpaddock |
blog:bpaddock:win_at_the_fda_hearing_on_fluoroquinolone_antibiotics [2016/03/22 00:01] (current) bpaddock Added Retinal Detachments |
||
|---|---|---|---|
| Line 3: | Line 3: | ||
| The nearly unanimous conclusion of the FDA advisory panel states that the current labelling to support Fluoroquinolone antibiotics use for sinusitis, bronchitis and uUTI is NOT justified. | The nearly unanimous conclusion of the FDA advisory panel states that the current labelling to support Fluoroquinolone antibiotics use for sinusitis, bronchitis and uUTI is NOT justified. | ||
| - | Eyes and Ears where not considered. In the opening remarks the FDA Chair said that //detached retinas due to these drugs would not be considered// today [Nov 5th 2015]. //When// will they? How many people think about how taking an antibiotic will make them go blind. :-( | + | Eyes and Ears where not considered. In the opening remarks the FDA Chair said that //detached retinas due to these drugs would not be considered// today [Nov 5th 2015]. //When// will they? How many people think about how taking an antibiotic will make them go blind. :-( [ New paper just published about FQ's being linked to Retinal Detachment: http://medicalresearch.com/ophthalmology/fluoroquinolones-linked-to-increase-in-retinal-detachments/22538/ Paywall version of the actual report: http://archopht.jamanetwork.com/article.aspx?articleid=2499851 ] |
| Note: The advisory committee made its recommendations, but now that has be evaluated by the FDA itself do decide what to do. They could decide to do nothing at all (not likely due to all the press there), take it off the market (what I want but not likely), change the labels, or the last option is require the patient to sign off that they understand the devastating effects before taking any of these drugs; [[http://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm|A Brief Overview of Risk Evaluation and Mitigation Strategies (REMS)]]. | Note: The advisory committee made its recommendations, but now that has be evaluated by the FDA itself do decide what to do. They could decide to do nothing at all (not likely due to all the press there), take it off the market (what I want but not likely), change the labels, or the last option is require the patient to sign off that they understand the devastating effects before taking any of these drugs; [[http://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm|A Brief Overview of Risk Evaluation and Mitigation Strategies (REMS)]]. | ||
